MT1G and cancer: Interestingly, we observed no induction of MT1G in primary human hepatocytes, and a striking specificity was also observed when sorafenib was compared with a panel of other clinically-approved kinase inhibitors in terms of ability to induce MT1G. Our study therefore identifies MT1G as a gene whose expression levels reflect the specific effect of sorafenib on the redox metabolism of cancer cells.